医学
阿哌沙班
拜瑞妥
心肌梗塞
阿司匹林
急性冠脉综合征
血栓
心脏病学
内科学
冲程(发动机)
溶栓
不利影响
临床试验
氯吡格雷
重症监护医学
心房颤动
华法林
工程类
机械工程
作者
Vikrant Rai,Marcus Balters,Devendra K. Agrawal
标识
DOI:10.31083/j.rcm.2019.04.56
摘要
Atherosclerosis is a leading cause of cardiovascular and neurological ischemic events. Plaque rupture leads to the exposure of highly thrombogenic material with blood and results in the activation of the coagulation cascade, thrombus formation, and embolic events. Although antiplatelets and anticoagulants are used to prevent thromboembolic episodes, bleeding episodes remain the major adverse effect. Decreased ischemic events have been reported while comparing oral rivaroxaban and apixaban with aspirin to improve the therapeutic outcome in several clinical trials, including Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51, Apixaban for Prevention of Acute Ischemic and Safety Events, and GEMINI-ACS-1 phase II clinical trials. However, there were bleeding episodes. Thus, there is an unmet need for better therapeutic strategies. Therefore, the current focus is to target Factors IX, XI, and XII to develop safer and efficient strategies. In this article, we critically reviewed and discussed the limitations of current therapies and the potential of targeting Factors IX, XI, and XII for anticoagulant therapy in atherothrombosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI